On May 19, 2025, HC Wainwright & Co. maintained its "Buy" rating for Y-mAbs Therapeutics (YMAB, Financial), a biopharmaceutical company focused on developing therapeutic antibodies for oncology. The rating remains consistent with previous analyses.
However, analyst Robert Burns adjusted the price target for (YMAB, Financial) from $12.00 to $11.00 USD, marking a decrease of 8.33%. This adjustment reflects a revised outlook on the company's stock potential in the coming periods.
Investors and market watchers are advised to take note of the updated price target, although the maintained "Buy" rating indicates continued confidence in the potential of Y-mAbs Therapeutics (YMAB, Financial).